Hepion Pharmaceuticals, Inc. (HEPA)
NASDAQ: HEPA · IEX Real-Time Price · USD
0.790
-0.230 (-22.56%)
Jul 22, 2024, 10:14 AM EDT - Market open
Hepion Pharmaceuticals Employees
Hepion Pharmaceuticals had 22 employees as of December 31, 2023. The number of employees decreased by 3 or -12.00% compared to the previous year.
Employees
22
Change (1Y)
-3
Growth (1Y)
-12.00%
Revenue / Employee
n/a
Profits / Employee
-$1,750,906
Market Cap
5.46M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
CareMax | 1,450 |
Ainos | 46 |
TFF Pharmaceuticals | 19 |
Soligenix | 15 |
Sonoma Pharmaceuticals | 10 |
Pasithea Therapeutics | 8 |
Oragenics | 5 |
Titan Pharmaceuticals | 4 |
HEPA News
- 3 months ago - Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH' Trial - GlobeNewsWire
- 4 months ago - Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell - GlobeNewsWire
- 5 months ago - Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds - GlobeNewsWire
- 7 months ago - Hepion Pharmaceuticals to Present at NASH-TAG 2024 - GlobeNewsWire
- 8 months ago - Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes - GlobeNewsWire
- 8 months ago - Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit - GlobeNewsWire
- 9 months ago - Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH' Liver Function Trial of Rencofilstat - GlobeNewsWire
- 9 months ago - Hepion Pharmaceuticals' Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model - GlobeNewsWire